Mariano Barbacid, a distinguished Spanish researcher and pioneer in the fight against cancer, has recently unveiled a significant breakthrough in the battle against pancreatic cancer. During an appearance on television, he made an urgent plea for a funding of 30 million euros to initiate human clinical trials. While his work has successfully eradicated the disease in mice, this request has sparked a profound division in public opinion.
A promising breakthrough (in mice)
Leading the experimental oncology group at the CNIO in Spain, Mariano Barbacid and his team have developed a tri-therapy that combines three drugs targeting critical proteins: KRAS, EGFR, and STAT3. In their studies with mice, pancreatic tumors completely disappeared without significant relapse, even after the treatment was halted, and without severe side effects. These findings, published in the journal PNAS, bring hope against this aggressively lethal cancer, which has a survival rate of less than 10% at five years.
Funding poses a colossal challenge
Barbacid estimates that at least 30 million euros are needed to transition to human clinical trials, a complex process that could take 2-3 years and involves testing three concurrent medications. He emphasizes the urgent need for support, warning that “delays could cost thousands of lives.” While the results are encouraging, experts caution that “animal successes” do not always translate to human outcomes, necessitating thorough validation.
Controversy on social media
- Reactions online have been passionate and polarized. On one side, there is enthusiasm: “A boxer makes 30 million in one or two fights. A footballer in a year. It would be a disgrace for humanity not to give 30 million to this man to launch trials that could save millions of lives.”
- On the other, skepticism persists: “Everyone asks, ‘where are the billionaires?’ They know this is a scam. Human trials would cost a billion. Instead of asking ‘where to invest?’, ask yourself ‘why not invest?’ That’s what billionaires do.”
Mariano Barbacid’s plea for 30 million euros has crystallized a vital debate: should we invest heavily in this validated tri-therapy against pancreatic cancer, or should we wait for further guarantees? Balancing legitimate hope with scientific caution, this controversy underscores the urgent need to fund research against a “silent killer,” which could potentially save millions.

